Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:

Immunovia Interim report, January-March 2017

April 20, 2017

“During the quarter we reported from a significant study that showed our ability to differentiate between SLE and other common autoimmune diseases. The very good results of the study, which indicated that SLE can be differentiated with 96% accuracy against a mix of healthy, rheumatoid arthritis, Sjögren’s disease and vasculitis patient samples, give us a very strong reason to invest further in the autoimmune area.”

“Also during the quarter we identified retrospective biobanks that contain relevant and well-documented blood samples from individuals who are afflicted with pancreatic cancer after being diagnosed with diabetes, and we will now conclude an agreement giving us access to these individuals so that we can perform the retrospective study we announced earlier.”

“We are now planning the details of our market access program and preparing those marketing activities that will best create awareness among key decision-makers about the link between pancreatic cancer and diabetes and the possibilities that our test offer for improved survival.”

Key indicators

Key indicators (SEK thousand unless otherwise stated) 1 Jan-31 March 2017 1 Jan-31 March 2016 Full year 2016
Net sales 28 0 177
Operating earnings -7 870 -2 435 -14 978
Earnings before tax -7 771 -2 406 -14 723
Net earnings -7 771 -2 406 -14 723
Earnings per share before and after dilution (SEK/share) -0,46 -0,17 -0,98
31 March 2017  31 March 2016  31 Dec. 2016
Equity ratio, % 97 97 98
No. of shares at the end of the period 16 804 059 14 291 216 16 804 059
Average number of shares before and after dilution 16 804 059 14 291 216 14 985 688

This financial statement has been produced in accordance with IFRS for the Immunovia Group, which comprises Immunovia AB and the wholly-owned subsidiary Immunovia Inc.

Immunovia is focused on fundamentally transforming diagnosis of complex forms of cancer and autoimmune diseases. The antibody-based platform, IMMray™, is the result of 15 years of research at CREATE Health – the Center for Translational Cancer Research at Lund University, Sweden. IMMray™ is a technology platform for the development of diagnostic tests and the company’s

primary test. IMMray™ PanCan –d is the first test in the world for early diagnosis of pancreatic cancer.

  •  It is planned to launch IMMray™ PanCan –d on the American and European markets with sales to out-of-pocket customers, to start when the accreditation and production upscaling have been completed, with revenues expected to begin in 2018. IMMray™ PanCan –d will address a market that in total is worth around SEK 30 billion.
  •  Immunovia sees great potential in the development of tests for other unsolved problems in cancer and autoimmune diseases via its IMMray™ platform. The next focus area will be tests within SLE, based on the positive results announced in early 2017. 

For more information, please contact:

Mats Grahn  

Chief Executive Officer, CEO, Immunovia 

Tel.: +46-70-5320230 


About Immunovia

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: 

This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above. 

Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit